Trial Profile
Phase 1 Trial of BC2059 (Tegavivint) in Patients With Unresectable Desmoid Tumor
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 May 2023
Price :
$35
*
At a glance
- Drugs Tegavivint (Primary)
- Indications Fibroma; Sarcoma
- Focus Adverse reactions; First in man
- Sponsors Iterion Therapeutics
- 19 Apr 2023 Results assessing Serum protein changes in patients with desmoid tumors responsive to the TBL1 inhibitor presented at the 114th Annual Meeting of the American Association for Cancer Research
- 08 Jun 2022 Status changed from active, no longer recruiting to completed.
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology